Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia
Carvajal L, Ben-Neriah D, Senecal A, Bernard L, Narayanagari S, Kenworthy C, Thiruthuvanathan V, Guerlavais V, Annis D, Bartholdy B, Will B, Anampa J, Mantzaris I, Aivado M, Singer R, Coleman R, Verma A, Steidl U. Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia. Blood 2017, 130: 795. DOI: 10.1182/blood.v130.suppl_1.795.795.Peer-Reviewed Original ResearchAML cell linesAML patient cellsAML cellsMDM2 inhibitionHealthy controlsLeukemic stemCell linesAge-matched healthy controlsWild-type p53Significant improved survivalProgenitor cellsAML xenograft modelStem cell-enriched populationAnti-leukemic effectsPatient cellsPatient undergoing treatmentAcute myeloid leukemiaCellular proliferationNovel therapeutic strategiesCell-enriched populationsTarget gene p21Primary cellsTP53 tumor suppressor geneObjective responseImproved survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply